United States: A Primer On Precision Medicine: The Legal And Ethical Considerations Faced By Modern Medicine's New Frontier

Last Updated: April 5 2018
Article by Elizabeth Scarola

The National Institutes of Health (NIH) defines "precision medicine" as

[A]n emerging health care model for disease treatment and prevention strategies that takes into account each person's genetic variations, environment and lifestyle.1

Precision medicine was thrust into the national conversation in 2015 when President Obama announced a $215 million U.S. funding commitment known as the Precision Medicine Initiative (PMI).2 In President Obama's words, the goal of precision medicine is to provide clinicians with new tools, knowledge, and therapies that will enable them to select "the right treatments, at the right time, every time to the right person."3

PMI drastically expanded precision medicine's presence in scientific research. As evidence, later this year, the PMI cohort program, "All of Us," will begin enrolling participants in a million person data set of genetic, lifestyle, and health information for further study of the interaction of genetics, environment, and lifestyle.4

Though scientists disagree about the extent to which precision medicine will translate into genuine improvements in health care delivery, even the most skeptical of experts cannot deny recent advancements in genetic testing and targeted therapeutics.5

Genetic Testing

Laboratories across the world assess risk and diagnose disease by analyzing genomes.6 The advent of 23and Me and other direct-to-consumer genetic testing products permit patients from their homes and personal computers to identify and assess their unique risk of developing disease.7

Although early genetic tests were developed to detect rare, relatively straightforward single-gene variations that were highly correlated with specific diseases, today's genetic tests (e.g., next generation sequencing (NGS)) are able to detect a wide range of genetic variants from a single sample.8 NGS allows scientists to identify more common, complex diseases and provides patients information to assess their individual risk of developing a myriad of diseases.9 In 2018, a single laboratory can sequence an entire human genome in less than 24 hours for just under $1,000.10 For less than $200, 23andMe offers consumers "genetic health risk reports" that detect variants related to late-onset Alzheimer's disease, Parkinson's disease, alpha-1 antitrypsin deficiency, celiac disease, hereditary hemochromatosis, hereditary thrombophilia, and age-related macular degeneration.11

Targeted Therapeutics

Even more astounding is that scientists can now offer certain patients targeted treatments for a variety of illnesses and conditions.12 These targeted therapeutics provide medicines specified to treat individual genetic mutations with exactitude.13 The Food and Drug Administration (FDA) has approved a number of these medications.14 To name a few, targeted therapeutics are now made available for certain breast cancers, melanomas, colorectal cancers, leukemias, lymphomas, ovarian cancers, pancreatic cancers, rheumatoid arthritis, and lupus conditions.15

In addition, recent advances in Clustered Regularly Interspersed Short Tandem Repeat (CRISPR) technology now allow scientists to artificially alter genes; the promise of CRISPR technology knows no bounds.16

Precision medicine's emergence in modern day medicine is here; and, the potential that the field offers is vast. However, its promise must manifest itself within our current legal and regulatory system; and, as every health care attorney knows, innovation is often fraught with complex and sometimes novel legal and regulatory barriers.

Pre-Market Approval and Clinical Oversight: FDA and CMS

[T]he FDA is currently finding its regulatory foothold during [this] transition in the practice of medicine.17

Two federal regulatory agencies currently oversee the development of genetic diagnostic tests and targeted therapeutics: the FDA and the Centers for Medicare & Medicaid Services (CMS).

The FDA is responsible for protecting and promoting public health by assuring "the safety, effectiveness, [and] quality" of medical drugs and devices by the authority granted to it under the Federal Food, Drug and Cosmetic Act (FDCA) and the Medical Device Amendments of 1976.18 Consequently, the FDA is a gatekeeper to advances in precision medicine.

For example, the FDA regulates in vitro diagnostic tests (IVDs) as a subset of medical devices.19 FDA approval of medical devices typically requires analytical and clinical validation.20 In the case of IVDs, manufacturers must prove that an IVD can (1) accurately identify a sample (i.e., accurately read a specific set of DNA bases in the human genome) and (2) link particular genetic variants to specific diseases (i.e., provide meaningful clinical information).21 Though this regulatory threshold seems simple enough, a narrow interpretation of the pre-market approval regulatory framework could lead to an unintended absurdity: namely that because the FDA typically bases its pre-market approval decision on evidence dependent upon large, randomized clinical trials, the FDA could arguably require separate analytical studies to prove the analytical and clinical validation of each of the many billion nucleotides in the human genome.22

Footnotes

1 Nat'l Insts. of Health, Precision Medicine (Jan. 11, 2018), available at http://ghr.nlm.nih.gov/handbook/precisionmedicine?show=all.

2 Dianne Nicol, Tania Bubela, Don Chalmers, et. al., Precision medicine: drowning in a regulatory soup?, J. Law and the Biosciences (May 4, 2016), available at https://www.researchgate.net/profile/Jennifer_Fleming4/publication/301913566_Precision_Medicine_Drowning_in_a_Regulatory_Soup/links/572ff82e08aee022975b7023/Precision-Medicine-Drowning-in-a-Regulatory-Soup.pdf.

3 Remarks by the President on Precision Medicine (Jan. 30, 2015), available at https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/remarks-president-precision-medicine.

4 The Precision Medicine Initiative Cohort Program—Building a Research Foundation for 21st Century Medicine (Sept. 17, 2015), available at https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-20150917-2.pdf.

5 Richard Harris, Will Gathering Vast Troves of Information Really Lead to Better Health?, NPR (Dec. 28, 2017), available at https://www.npr.org/sections/health-shots/2017/12/28/572677879/will-gathering-vast-troves-of-information-really-lead-to-better-health.

6 Id.

7 George J. Annas and Sherman Elias, 23andMe and the FDA, N. Eng. J. Med. (Mar. 13, 2014), available at http://www.nejm.org/doi/full/10.1056/nejmp1316367.

8 Francis S. Collins & Margaret A. Hamburg, First FDA Authorization for Next-Generation Sequencer, 369 N. Eng. J. Med. 2369, 2369 (2013), available at http://www.nejm.org/doi/full/10.1056/NEJMp1314561.

9 Francis S. Collins & Harold Varmus, A New Initiative on Precision Medicine, 372 N. Eng. J. Med. 793 (2015), available at http://www.nejm.org/doi/full/10.1056/NEJMp1500523.

10 Peter Dockrill, You Can Now Sequence Your Entire Genome For Under $1,000 (Mar. 9, 2016), available at https://www.sciencealert.com/you-can-now-sequence-your-entire-genome-for-under-1-000.

11 23andMe Genetic Health Risk Reports: What you should know, available at https://www.23andme.com/test-info/genetic-health/.

12 Hait, William N., Targeted cancer therapeutics, Cancer research69.4 (2009): 1263-1267, available at https://www.ncbi.nlm.nih.gov/pubmed/19208830.

13 Id.

14 Examples of FDA-approved drugs tailored to individuals with specific molecular profiles include Imanitib, Dasatinib, Nilotinib, Bosutinib, Pontatinib, Erlotinib, Afatinib, T ramatenib, Crizotinib, Cetuximab, etc. See generally Overview of Targeted Therapies for Cancer, available athttps://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer/. .

15 Id.

16 Cong, Le, et al. Multiplex genome engineering using CRISPR/Cas systems, Science 339.6121 (2013): 819-823, available at https://www.ncbi.nlm.nih.gov/pubmed/23287718.

17 Kwon, Sarah Y., Regulating Personalized Medicine, Berkeley Tech. L.J. 31 (2016): 931, available at https://scholarship.law.berkeley.edu/cgi/viewcontent.cgi?referer=https://www.google.com/&httpsredir=1&article=2129&context=btlj.

18 U.S. Food & Drug Admin., FDA Fundamentals, available at http:///www.fda.gov/AboutFDA/Transparecy/Basics/ucm192695.htm.

19 FDCA defines IVDs as "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is . . . intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease." 21 U.S.C. § 321 (h)(2)(2012). See U.S. Food & Drug Admin., Draft Guidance for Industry, Clinical Laboratories, and FDA Staff: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) 5 (Oct. 3, 2014), available at http://www.fda.gov/downloads/medical-devices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf.

20 21 U.S.C. ch. 9 § 301 et seq.

21 Olsen, Dana, and Jan Trøst Jørgensen, Companion diagnostics for targeted cancer drugs–clinical and regulatory aspects, Frontiers inoncology 4 (2014), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032883/.

22 Lander, Eric S, Cutting the Gordian helix—regulating genomic testing in the era of precision medicine, N. Engl. J. Med. 372.13 (2015): 1185-1186, available at http://www.nejm.org/doi/full/10.1056/NEJMp1501964.

To view the full article, please click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions